Compare ConocoPhillips (COP) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Davita Inc — how do they compare? ConocoPhillips trades at $110.19 (market cap $136.29B), while Davita Inc trades at $227.55 (market cap $14.92B). The key difference: ConocoPhillips is far larger — about 9.1× Davita Inc's market cap, and ConocoPhillips pays a 3% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| COP | DVA | |
|---|---|---|
Market Cap | $136.29B | $14.92B |
Sector | Energy | Health |
52-Week High | $133.80 | $235.71 |
52-Week Low | $85.66 | $103.87 |
Enterprise Value | $153.25B | $27.47B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $112.85, up 3.49% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q1 2026 earnings, beating EPS estimates but showing declining revenue and net income margins since 2022. Recent news highlights oil price volatility and geopolitical risks influencing energy stocks.
COP offers value with a P/E of 19.13 and bullish analyst targets averaging $137.14, but faces headwinds from falling profitability and oil market instability. Investment appeal hinges on execution amid volatile commodity prices and competitive pressures.
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
